ReviewInternational journal of molecular sciences2022
Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.Molecules (Basel, Switzerland) · 2026Review
- Tattoos and risk of cutaneous melanoma and nonmelanoma skin cancer in France.Journal of the National Cancer Institute · 2026Article
- Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Calcium/Aluminum-Cored Asymmetric Bilayer Nanoparticles for Codelivery of Ziyuglycoside II and PD-L1 siRNA Exert Anti-Breast Tumor Effects.Pharmaceutics · 2026Article
- Challenges and opportunities on achieving an adequate delivery efficiency and immunogenicity with peptide-based anticancer vaccines.Advanced drug delivery reviews · 2025Review
- Nano/Micro-Enabled Modification and Innovation of Conventional Adjuvants for Next-Generation Vaccines.Journal of functional biomaterials · 2025Review
- The role of NLRP3 inflammasome activation in proinflammatory and cytotoxic effects of metal nanoparticles.Archives of toxicology · 2025Review
- Article
- Anti-tumor effect and immune-related mechanism study of compound aluminum sulfate injection in transplanted tumor-bearing mice.Frontiers in immunology · 2025Article
- Harnessing cytokines: innovative adjuvants for improved veterinary vaccine efficacy.Frontiers in immunology · 2025Review
- Next-generation aluminum adjuvants: Immunomodulatory layered double hydroxide NanoAlum reengineered from first-line drugs.Acta pharmaceutica Sinica. B · 2024Review
- Emerging Cationic Nanovaccines.Pharmaceutics · 2024Review
- Antioxidants in Male and Animal Reproduction: Applications and Critical Issues.Antioxidants (Basel, Switzerland) · 2024Article
- Current Progress in the Science of Novel Adjuvant Nano-Vaccine-Induced Protective Immune Responses.Pathogens (Basel, Switzerland) · 2024Review
- Evaluation of Aluminium Hydroxide Nanoparticles as an Efficient Adjuvant to Potentiate the Immune Response againstVaccines · 2023Article
- Research Progress of Aluminum Phosphate Adjuvants and Their Action Mechanisms.Pharmaceutics · 2023Review
- Article
- Prospects for the Use of Metal-Based Nanoparticles as Adjuvants for Local Cancer Immunotherapy.Pharmaceutics · 2023Review
- Nanoclays: Promising Materials for Vaccinology.Vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Aluminium (Al) compounds are used as adjuvants in human and veterinary prophylactic vaccines due to their improved tolerability compared to other adjuvants. These Al-based adjuvants form microparticles (MPs) of heterogeneous sizes ranging from ~0.5 to 10 µm and generally induce type 2 (Th2)-biased immune responses. However, recent literature indicates that moving from micron dimension particles toward the nanoscale can modify the adjuvanticity of Al towards type 1 (Th1) responses, which can potentially be exploited for the development of vaccines for which Th1 immunity is crucial. Specifically, in the context of cancer treatments, Al nanoparticles (Al-NPs) can induce a more balanced (Th1/Th2), robust, and durable immune response associated with an increased number of cytotoxic T cells compared to Al-MPs, which are more favourable for stimulating an oncolytic response. In this review, we compare the adjuvant properties of Al-NPs to those of Al-MPs in the context of infectious disease vaccines and cancer immunotherapy and provide perspectives for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.